Unfortunately, despite promising early-phase results, the STELLAR-3 and -4 trials failed to reach their primary endpoint and show improvement in liver fibrosis with the ASK-1 inhibitor selonsertib [124,125]. Here, MAP3K5 is linked to Hepatic fibrosis.